SEATTLE, Wash. — The National Institutes of Health has selected Kaiser Permanente Washington as the first to begin clinical testing of a vaccine for the coronavirus.
A Kaiser spokesperson told KGMI in an email statement that they will recruit 45 healthy people ages 19 to 55 to participate in the trial, which is expected to last 13 months.
The trial consists of three phases, with the first phase testing dose safety and whether those doses are producing an immune response.
The first phase of the trial will not study the effectiveness of the vaccine in preventing coronavirus infection.
The trial will not include any form of live virus and participants will not be exposed to the virus.